<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056600</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DMCL004</org_study_id>
    <nct_id>NCT02056600</nct_id>
  </id_info>
  <brief_title>BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/1000mg in Comparison to Each Component Gemigliptin 50mg and Metformin HCl Extended Release 1000mg Administered in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of
      gemigliptin 50mg and metformin HCl extended release 1000mg in comparison to each component
      administered in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>up to 48h post-dose</time_frame>
    <description>To evaluate AUClast of gemigliptin and metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 48h post-dose</time_frame>
    <description>To evaluate Cmax of gemigliptin and metformin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>G+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of gemigliptin50mg/metformin HCl sustained release 1000mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemigliptin and metformin HCl extended release</intervention_name>
    <description>Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day</description>
    <arm_group_label>G+M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemigliptin/metformin HCl sustained release</intervention_name>
    <description>Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male adults at age between 20 to 45 at the time of the screening

          -  ThoseSubjects whose BMI measurement at screening visit is between 18 and 27 kg/m2

          -  Subjects with fasting plasma glucose (FPG) of 70-125 mg/dL at screening visit

          -  Subject who has voluntarily decided to participate in this clinical trial and onsented
             in writing

        Exclusion Criteria:

          -  Subjects who have a past or present clinically significant disease such as hepatic,
             renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neurological,
             hemato-oncological, or cardiovascular disorder

          -  Subjects who have a past history of gastrointestinal disease (e.g. Crohn's disease,
             ulcer, etc.) or surgery (however, simple appendectomy and hernioplasty are not
             included) that can affect the absorption of drugs

          -  Subjects with a medical history of allergic reaction to other drugs including the
             investigational products or clinically significant hypersensitivity reaction

          -  Subjects who have a history of drug abuse

          -  Subjects who have shown positive reaction to drugs that may be abused from a urine
             drug screening

          -  Subjects who took other investigational product in other trials within 90 days before
             the first administration of this investigational product

          -  Subjects who had whole blood donation within 60 days or component blood donation
             within 30 days before the first administration of the investigational product, or
             transfusion within 30 days before the first administration

          -  Subjects who have taken a drug which is expected to have an effect on the clinical
             trial within 14 days before the date of the first administration of the
             investigational product or have had any food that is expected to have an effect on the
             clinical trial within 7 days (e.g. drinks containing caffeine, grapefruit juice, etc.)

          -  Subjects who have had alcohol containing drinks 3 times or more per week within one
             month before the screening visit or cannot abstain from drinking after completing the
             informed consent form for the participation in the study to the end of the clinical
             trial

          -  Subjects who have smoker more than 10 cigarettes per day within the recent one month
             at the screening visit or cannot refrain from smoking the clinical trial period

          -  In the vital signs measured in sitting position at the screening visit, subjects who
             have showed a systolic blood pressure of &lt; 90 mmHg or &gt; 145 mmHg, a diastolic blood
             pressure of &gt; 95 mmHg or &lt; 60 mmHg) , or a pulse rate of &gt; 110 bpm or &lt; 40 bpm

          -  Subjects who showed the following findings in the tests conducted during the screening
             period:

          -  In excess of 1.5 times the upper normal limit (UNL) in hepatic enzyme (AST and ALT)
             values

          -  The creatinine clearance calculated by Cockcroft-Gault equation is 80 mL/min or less

          -  Positive result in serum test (hepatitis type B test, hepatitis type C test, Human
             Immunodeficiency Virus (HIV) test, syphilis test)

          -  QTc &gt; 450 msec in ECG or a clinically significant abnormal rhythm

          -  Subjects who are considered to be unsuitable in conducting the clinical trial for
             other reason at the principal investigator's discretionary judgment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

